Drugs / KJ015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07036185 | Jun 2025 → Dec 2026 expected | bile duct cancer, breast cancer, colorectal cancer, gastroesophageal cancer +2 | Shanghai Bao Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KJ015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07036185 ↗ |
| Route | Subcutaneous | “KJ015 is administered via subcutaneous injection.” NCT07036185 ↗ |